ClinicalTrials.gg
Not yet recruitingNCT07384923Updated Aug 25, 2026

The Effect of Vibration Devices on Pain and Discomfort During Local Anesthesia Administration in Children

An interventional study of DentalVibe intraoral vibration device and Buzzy Bee® extraoral vibration device in Children's Anxiety Levels, Children's Behavior and Physiological Changes (Heart Rate), sponsored by King Abdulaziz University. Not yet recruiting at 1 site in Saudi Arabia. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by King Abdulaziz University · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Pain with a site in Saudi Arabia — 4 open to participants now, 5 under way, 1 of them phase 3. Pain · Saudi Arabia.

Planned enrollment
35th of 39
20 · median 55
Started
2026
with 1 other
No phase
37 of 39
4 open now
Registered
34th of 39
by date
Lead sponsor
6 of 39
King Abdulaziz University

Among the 39 studies in Pain with a site in Saudi Arabia, this one is the 35th largest by planned enrollment, is one of 2 that started in 2026, is one of 37 with no phase, and was the 34th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 39 studies in Pain with a site in Saudi Arabia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Saudi Arabia have not opened yet or have stopped. Only those recruiting at a site in Saudi Arabia →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Pain with a site in Saudi Arabia, or all of them as a file.
02

Study summary

This split-mouth randomized clinical trial will be conducted at the Department of Pediatric Dentistry, King Abdulaziz University Dental Hospital (KAAUDH). The inclusion criteria will include healthy, non-anxious, cooperative children aged six to 12 who require non-urgent dental treatment involving at least one pair of contralateral maxillary molars needing buccal infiltration anesthesia with no previous dental history or experience.

The children will be screened for eligibility, and a single trained dental intern will approach the parents or guardians of eligible children. Those who agree to be screened for participation in the study will be asked to sign an Arabic consent form. Before the scheduled screening appointment, children's anxiety levels will be assessed using a high score on the Abeer Children Dental Anxiety Scale (ACDAS) in the waiting area.

During the appointment, a single trained dental intern will perform the dental examination and prophylaxis, while two trained and calibrated dental interns will assess children's behavior using the Frankl Behavior Rating Scale.

Children found to be non-anxious based on their ACDAS score and cooperative or definitely cooperative based on the Frankl Behavior Rating Scale will be considered eligible for the study. Two treatment appointments will be scheduled for them, and consent and assent forms for participation in the study will be obtained.

Computer randomization will be performed to determine the treatment sequence (DentalVibe intraoral vibration device followed by Buzzy Bee® extraoral vibration device, or vice versa) and the site (right or left). Randomization will be performed before the first scheduled treatment appointment.

The subjects will be seated in the dental chair for five minutes to acclimate to the environment. To measure the physiological changes of the participating subjects, a pulse oximeter device (OxyWatch, ChoiceMMed, Hamburg, Germany) will be applied, and a trained dental intern will record the baseline heart rate (HR). During the treatment, HR will also be recorded.

The tip of the DentalVibe intraoral vibration device will be gently placed on the mucobuccal fold above the tooth to be anesthetized. In contrast, the Buzzy Bee® extraoral vibration device will be positioned externally above the buccal infiltration site.

During maxillary buccal infiltration, all subjects will be videotaped using a high-resolution camera, focusing on the face and body. Later, two trained and calibrated evaluators will independently assess the child's behavior during the procedure using the Face, Legs, Activity, Cry, Consolability Scale (FLACC) Immediately after administering anesthesia, the subjects will be positioned upright, and the same trained dental intern will introduce the face version of the Visual Analogue Scale (VAS).

Finally, after completing both procedures, the subjects will be asked about their future preference for the vibration device. Due to the study's design, both the investigator administering the maxillary buccal infiltration and the subjects will not be aware of which group they belong to.

Read the detailed description

This split-mouth randomized clinical trial will be conducted at the Department of Pediatric Dentistry, King Abdulaziz University Dental Hospital (KAAUDH after obtaining ethical approval from the Research Ethics Committee of the Faculty of Dentistry, King Abdulaziz University (Reference No. 040-03-22). The study will adhere to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.

The inclusion criteria will include healthy, non-anxious, cooperative children aged 6 to 12 who require non-urgent dental treatment involving at least one pair of contralateral maxillary molars, requiring buccal infiltration anesthesia, with no previous dental history or experience.

The children will be screened for eligibility by two trained dental interns during their initial regular screening appointment at KAAUDH between September and December 2025. Healthy children aged six to 12 years who require non-urgent dental treatment involving at least one pair of contralateral maxillary molars needing buccal infiltration anesthesia with no prior dental experience will be eligible for screening.

A single trained dental intern approached the parents or guardians of eligible children. Those who agree to be screened for study participation will be asked to sign an Arabic consent form. Additionally, a screening assent will be obtained from children aged seven years and older. Before the scheduled screening appointment, children's anxiety levels will be assessed using a high score on the Abeer Children Dental Anxiety Scale (ACDAS) in the waiting area. Total scores range from 13 to 39; children scoring 26 or higher are considered anxious.

During the appointment, a single trained dental intern will perform the dental examination and prophylaxis using a low-speed handpiece and a rubber cup with prophylactic paste. Two trained and calibrated dental interns will assess children's behavior during the procedure using the Frankl Behavior Rating Scale.

Children found to be non-anxious based on their ACDAS score and cooperative or definitely cooperative based on the Frankl Behavior Rating Scale will be considered eligible for the study. Two treatment appointments will be scheduled for them, and consent and assent forms for participation in the study will be obtained. Children requiring urgent dental treatment, those with active infections at the injection site, non-Arabic speakers, children with high anxiety scores in the ACDAS, or those who are uncooperative during the screening appointment will be excluded and referred to be treated by a pediatric dentist at KAAUDH.

Computer randomization will be performed to determine the treatment sequence (DentalVibe intraoral vibration device followed by Buzzy Bee® extraoral vibration device, or vice versa) and the site (right or left). Randomization will be performed before the first scheduled treatment appointment.

Subjects will be divided into four groups. Those who first received maxillary buccal infiltration with the DentalVibe intraoral vibration device on the right side will be classified as group 1. Those who received it on the left side first will be classified as group 2. Meanwhile, subjects who received maxillary buccal infiltration with the Buzzy Bee® extraoral vibration device on the right side first will be classified as group 3, and those who received it on the left side first will be classified as group 4.

The subjects will be seated in the dental chair for five minutes to acclimate to the environment. To measure the physiological changes in the participating subjects, a pulse oximeter (OxyWatch, ChoiceMMed, Hamburg, Germany) will be used, and a trained dental intern will record the baseline heart rate (HR). During the treatment, HR will also be recorded at the application of topical anesthesia, activation of the vibration device, needle insertion, and immediately after the needle is withdrawn.

Before the procedure began, the assigned device will be introduced to the subjects as a tool that causes vibrations to reduce pain and discomfort. The DentalVibe intraoral vibration device will also be presented as a tool for retracting lips and cheeks.

The mucosa at the injection site will be dried with gauze, and 20% benzocaine will be applied for 60 seconds. The tip of the DentalVibe intraoral vibration device will be gently placed on the mucobuccal fold above the tooth to be anesthetized. In contrast, the Buzzy Bee® extraoral vibration device will be positioned externally above the buccal infiltration site. The device will be operated for five seconds before needle insertion. A 30-gauge G short needle will be used. The device will remain on during buccal infiltration with 2% Mepivacaine with 1:200,000 epinephrine (Scandicaine 2% special, Septodont, UK) until five seconds after the needle is fully withdrawn. A single-trained pediatric dentist performed all the maxillary buccal infiltration administration.

During maxillary buccal infiltration, all subjects will be videotaped using a high-resolution camera, focusing on the face and body. Later, two trained and calibrated evaluators will independently assess the child's behavior during the procedure using the Face, Legs, Activity, Cry, Consolability Scale (FLACC). To ensure calibration, before the study began, the evaluators will review the behavior of 15 randomly selected children who were videotaped receiving local anesthesia using the FLACC.

Immediately after administering anesthesia, the subjects will be positioned upright, and the same trained dental intern will introduce the face version of the Visual Analogue Scale (VAS), which assesses the subject's subjective pain and discomfort. Additionally, subjects' and parents' satisfaction with each dental vibration device will be assessed.

Finally, after completing both procedures, the subjects will be asked about their future preference for the vibration device. Due to the study's design, both the investigator administering the maxillary buccal infiltration and the subjects will not be aware of which group they belong to.

03

Conditions studied

  • Children's Anxiety Levels
  • Children's Behavior
  • Physiological Changes (Heart Rate)
  • Obejective Pain and Discomfort
  • Subjective Pain and Discomfort
  • Subjects' and Parents' Satisfaction
  • Subjects' and Parents' Future Preference

Keywords

  • Pain and discomfort
  • future preferece
  • satisfaction
  • Vibration Device
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy children
  2. Non-anxious
  3. cooperative
  4. Aged six to 12
  5. No previous dental history or experience.

5- Who required non-urgent dental treatment involving at least one pair of contralateral maxillary molars needing buccal infiltration anesthesia

Exclusion criteria

Exclusion Criteria:

  1. Children requiring urgent dental treatment
  2. Those with active infections at the injection site
  3. Non-Arabic speakers
  4. Children with high anxiety scores in the ACDAS
  5. Those who were uncooperative during the screening appointment
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Other
    The DentalVibe vibration device first on the right side then the Buzzy Bee® vibration device

    The DentalVibe intraoral vibration device first on the right side then the Buzzy Bee® extraoral vibration device on the left Side.

    Device: DentalVibe intraoral vibration device · Device: Buzzy Bee® extraoral vibration device

  • Other
    The DentalVibe vibration device first on the left side then the Buzzy Bee® vibration device

    The DentalVibe intraoral vibration device is first on the left side, then the Buzzy Bee® extraoral vibration device on the right Side.

    Device: DentalVibe intraoral vibration device · Device: Buzzy Bee® extraoral vibration device

  • Other
    The Buzzy Bee® vibration device first on the right side then the DentalVibe vibration device

    The Buzzy Bee® extraoral vibration device is first on the right side, then the DentalVibe intraoral vibration device on the left Side

    Device: DentalVibe intraoral vibration device · Device: Buzzy Bee® extraoral vibration device

  • Other
    The Buzzy Bee® vibration device first on the left side, then the DentalVibe vibration device

    The Buzzy Bee® extraoral vibration device is first on the left side, then the DentalVibe intraoral on the right side.

    Device: DentalVibe intraoral vibration device · Device: Buzzy Bee® extraoral vibration device

Interventions

  • DeviceDentalVibe intraoral vibration device

    DentalVibe intraoral vibration device.

  • DeviceBuzzy Bee® extraoral vibration device

    Buzzy Bee® extraoral vibration device

06

What researchers measure

Primary outcomes

  1. Physiological changes (heart rate(HR))

    Physiological changes (HR) of the participating subjects will be measured using a pulse oximeter device (OxyWatch, ChoiceMMed, Hamburg, Germany), and a trained dental intern will record it.

    Time frame: HR will be recorded at: 1- At baseline, onc subjects sat in the dental chair 2- At the application of topical anesthesia 3- At the activation of the vibration device 4- At needle insertion 5- Immediately after the needle is withdrawn.

  2. The subject's subjective pain and discomfort.

    Visual Analogue Scale (VAS), which assesses the subject's subjective pain and discomfort. The scale is a 10-cm line that indicates the level of pain and discomfort, with zero representing no pain and 10 representing the worst possible pain.

    Time frame: Immediately after the anesthesia administration

  3. Objective pain and discomfort

    Two trained and calibrated evaluators independently assessed the child's objective pain and discomfort during the procedure using the Face, Legs, Activity, Cry, Consolability Scale (FLACC). The FLACC scale ranges from 0 to 10, with 0 indicating no pain and 10 the worst possible pain.

    Time frame: During the anesthesia administration

Secondary outcomes

  1. Subjects' and parents' satisfaction with each dental vibration device

    Subjects' and parents' satisfaction with each dental vibration device will be assessed using a five-point Likert scale, where zero indicates "not satisfied at all" and 10 means "very satisfied."

    Time frame: Immediately after both vibration devices.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 3 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 3, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384923
Lead sponsor
King Abdulaziz University
Responsible party
Sara M.Bagher (Associate Professor, King Abdulaziz University) — Principal investigator
First posted
Feb 3, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 25, 2026

Study contacts

Sara Bagher, Associate Professor
Contact
sbagher@kau.edu.sa
00966547433525
Shahad Abudawood, Assistant Professor
Contact
sabudawood@kau.edu.sa
00966503611195

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion